Related Experiment Video
Updated: May 5, 2026
08:41
Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
Published on: June 3, 2019
9.5K
Adiponectin, type 2 diabetes and cardiovascular risk
Søren Lindberg1, Jan Skov Jensen2, Mette Bjerre3
1Bispebjerg University Hospital, Copenhagen, Denmark Gentofte University Hospital, Copenhagen, Denmark soerenli@hotmail.com.
European Journal of Preventive Cardiology
|November 23, 2013
Summary
Higher adiponectin levels are linked to a decreased risk of developing type 2 diabetes (T2DM) and subsequent cardiovascular (CV) events. This finding challenges previous associations of high adiponectin with increased CV risk.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Disease Research
- Diabetes Mellitus Research
Background:
- Adiponectin, an insulin-sensitizing hormone, is typically decreased in metabolic disorders like type 2 diabetes mellitus (T2DM).
- Contradictory findings link elevated adiponectin to increased cardiovascular (CV) disease and mortality, necessitating further investigation.
- The dual role of adiponectin in metabolic and cardiovascular health requires clarification regarding its association with T2DM and subsequent CV events.
Purpose of the Study:
- To investigate the relationship between plasma adiponectin levels and the incidence of T2DM.
- To examine the association between plasma adiponectin levels and the occurrence of subsequent CV events after T2DM diagnosis.
- To clarify the predictive role of adiponectin in the development of T2DM and associated cardiovascular risks.
Main Methods:
- Prospective cohort study involving 5349 community-dwelling men and women initially free of T2DM and CV disease.
- Plasma adiponectin levels were measured at baseline; participants were followed for a median of 8.5 years.
- Cox-regression analysis was employed to assess the association between adiponectin and incident T2DM and CV events, adjusting for multiple confounding factors.
Main Results:
- Increasing plasma adiponectin levels were independently associated with a significantly reduced risk of developing T2DM (HR 0.55 per doubling; p < 0.001).
- After T2DM diagnosis, the risk of a CV event more than doubled.
- Elevated adiponectin levels were also associated with a reduced risk of subsequent CV events in individuals with T2DM (HR 0.34 per doubling; p = 0.005).
Conclusions:
- Higher plasma adiponectin concentrations are independently associated with a decreased risk of developing T2DM.
- Increased adiponectin levels are linked to a reduced risk of subsequent cardiovascular events following T2DM diagnosis.
- These findings suggest a protective role for adiponectin against both T2DM incidence and its cardiovascular complications.
More Related Videos
10:40Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro
Published on: December 5, 2025
93.9K
06:35Author Spotlight: Insights into Cardiometabolic Diseases with Subcutaneous Adipose Tissue Microvasculature Studies
Published on: April 5, 2024
1.8K
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
36
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
36
01:26Type II Diabetes I: Introduction
57
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
57
01:26Type I Diabetes II: Pathophysiology
121
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
121
01:22Diabetes Mellitus: Type 2 and Gestational
5.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
01:19Type I Diabetes III: Clinical Manifestations
31
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
31
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
32
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
32